Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer out on Lancet Oncology buff.ly/4huOHek Multicentre, single-arm phase 2 trial evaluated the safety and efficacy of a novel treatment approach for patients with unresectable, locally advanced non-small-cell #LungCancer ( #NSCLC ), involving stereotactic body radiotherapy (SBRT) to the primary tumor, followed by standard chemoradiotherapy to the lymph nodes and consolidation immunotherapy with durvalumab. Sixty-one patients were enrolled, with a median follow-up of 29.5 months. The study reported a 1-year progression-free survival (PFS) of 62.7%, although it did not achieve the primary endpoint of significant improvement over historical controls. Treatment-related grade 3–4 adverse events included decreased neutrophil and white blood cell counts, and treatment-related deaths occurred in 7% of patients. Despite not meeting the primary endpoint, the treatment demonstrated favorable activity and safety profiles, forming the basis for an ongoing randomized phase 3 trial (NRG Oncology LU008). @DrJRadOnc @KMilehamMD @DrChrisCorso @AKesarwala @stuxrt Ping OncoAlert Rad Onc Faculty @MKnoll_MD @HenningWillers @fumikochino @_ShankarSiva @PercyLeeMD @Icro_Meattini @DrChowdharyMD @DrLesterColl @ErinGillespieMD @seanmmcbride @NiuSanford #OncoAlertAF @nataliagandur @acampsmalea @BiagioRicciutMD @yekeduz_emre @HHorinouchi @FadiHaddad_MD @Dr_Ivanoncologo @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK